About Us
Sulantrix is a UK-based Biotech company focused on modulating ‘zombie’ proteins belonging to the pseudokinase target class with new small molecule drugs to treat disease
Our Mission
To create medicines which provide a real benefit to patients suffering from diseases where treatment options aren’t available or where existing medicines have stopped working

Our Team

David Williams
CEO

Patrick Eyers
CSO

Peter Woodhall
CFO

Emma Fairweather
Screening Specialist

Yong Li
biochemist

Professor Sir Philip Cohen
SAB Member

Professor Elton Zeqiraj
SAB Member

Professor David Spring
SAB Member

Dr Karen Keeshan
SAB Member

Professor Natarajan Kannan
SAB Member

Dr Simon Cook
SAB Member
Scientific Advisory Board

Prof. Sir Philip Cohen
SAB Member

Prof. Elton Zeqiraj
SAB Member

Prof. David Spring
SAB Member

Dr Simon Cook
SAB Member

Prof. Natarajan Kannan
SAB Member

Dr Karen Keeshan
SAB Member

Clinical Need
The pseudokinase drug targets that Sulantrix are pursuing play central roles in a variety of hard-to-treat solid and blood-based cancers, fibrosis, neurodegeneration and age-related diseases..
Our key indications have significant unmet clinical need, where there are no current effective medicines or existing treatment no longer work. The medicines we are developing will be both primary major treatment options or work alongside existing treatments.
.
Science & Technology

Pseudokinases are catalytically sterile, in that they do not appear to function as enzymes in cells. However, their unique control functions in normal cells are subverted in diseases such as cancer, fibrosis, neurodegeneration, cardiovascular, inflammatory & age-related diseases making them very attractive drug targets. Sulantrix is particularly focused on the pseudokinase class, which can become dysregulated in many treatment refractory areas

News & Resources
EMBO Workshop – Pseudoenzyme functions across life – challenges and opportunities, 10-13 June, 2024, Girona, Spain.
Our CSO, Prof Patrick Eyers and screening specialist, Dr Emma Fairweather will be attending this exciting EMBO Pseudoenzyme workshop in Spain in June. Please feel free to come and chat about our ongoing therapeutic programmes.
Bio 2023 International Conference, Boston, USA, 5-8 June, 2023
Our CEO David Williams and CSO Patrick Eyers will be attending the Bio2023 conference at the Boston Convention & Exhibition Center Boston 5-8th June. Find us through the One-on-One Partnering system to hear about our exciting progress targeting pseudoenzymes for cancer therapy.
New University spin-out Sulantrix targeting untapped pseudoenzymes for new cancer medicines
A new University of Liverpool spin-out drug discovery company, Sulantrix (pseu-lan-tricks), is exploring new medicines targeting cancer in which previously untapped classes of pseudoenzymes are key.
Read About Our Science
Contact us
If you are interested in learning more about Sulantrix and our technology, or would like to join us on our journey, please get in touch.